This is a duplicate of my Dry Eye Digest blogspot blog - to see the full archives back to 2005, please click on that link.
Somehow outperforming Restasis sounds rather inevitable than impressive in this context, but nonetheless the drug sounds promising.
Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye Disease: Results from a Phase 1/2 Trial.
To evaluate safety and efficacy of topical ophthalmic tofacitinib (CP-690,550), a novel Janus kinase inhibitor, in treating dry eye disease (DED).
A phase 1/2 prospective, randomized, double-masked,